|
Gene: SAP130 |
Gene summary for SAP130 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SAP130 | Gene ID | 79595 |
Gene name | Sin3A associated protein 130 | |
Gene Alias | SAP130 | |
Cytomap | 2q14.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9H0E3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79595 | SAP130 | HCC1_Meng | Human | Liver | HCC | 3.94e-17 | -5.59e-04 | 0.0246 |
79595 | SAP130 | HCC1 | Human | Liver | HCC | 1.70e-03 | 2.99e+00 | 0.5336 |
79595 | SAP130 | HCC2 | Human | Liver | HCC | 1.18e-07 | 3.08e+00 | 0.5341 |
79595 | SAP130 | S014 | Human | Liver | HCC | 2.96e-07 | 2.64e-01 | 0.2254 |
79595 | SAP130 | S015 | Human | Liver | HCC | 8.77e-05 | 2.91e-01 | 0.2375 |
79595 | SAP130 | S016 | Human | Liver | HCC | 5.36e-08 | 2.75e-01 | 0.2243 |
79595 | SAP130 | S027 | Human | Liver | HCC | 1.68e-03 | 3.71e-01 | 0.2446 |
79595 | SAP130 | S028 | Human | Liver | HCC | 1.18e-09 | 4.05e-01 | 0.2503 |
79595 | SAP130 | S029 | Human | Liver | HCC | 1.51e-03 | 2.65e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SAP130 | SNV | Missense_Mutation | c.1829N>T | p.Gln610Leu | p.Q610L | Q9H0E3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-78-8640-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SAP130 | SNV | Missense_Mutation | novel | c.2697G>C | p.Lys899Asn | p.K899N | Q9H0E3 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.496) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SAP130 | SNV | Missense_Mutation | novel | c.3193C>A | p.Leu1065Ile | p.L1065I | Q9H0E3 | protein_coding | tolerated_low_confidence(0.12) | possibly_damaging(0.6) | TCGA-86-7954-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
SAP130 | SNV | Missense_Mutation | novel | c.2293G>C | p.Ala765Pro | p.A765P | Q9H0E3 | protein_coding | tolerated_low_confidence(0.11) | benign(0.001) | TCGA-J2-A4AD-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SAP130 | SNV | Missense_Mutation | c.1760N>C | p.Gly587Ala | p.G587A | Q9H0E3 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.879) | TCGA-18-3414-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
SAP130 | SNV | Missense_Mutation | c.315G>T | p.Gln105His | p.Q105H | Q9H0E3 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.994) | TCGA-33-4583-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SAP130 | SNV | Missense_Mutation | c.2199G>T | p.Met733Ile | p.M733I | Q9H0E3 | protein_coding | tolerated_low_confidence(0.1) | benign(0.006) | TCGA-39-5027-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SAP130 | SNV | Missense_Mutation | c.914N>T | p.Thr305Met | p.T305M | Q9H0E3 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.999) | TCGA-46-3768-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD | |
SAP130 | SNV | Missense_Mutation | novel | c.2305N>T | p.Pro769Ser | p.P769S | Q9H0E3 | protein_coding | deleterious_low_confidence(0.04) | benign(0.275) | TCGA-56-7222-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
SAP130 | SNV | Missense_Mutation | novel | c.2480A>G | p.Asp827Gly | p.D827G | Q9H0E3 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.856) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
79595 | SAP130 | NA | SPLICEOSTATIN-A | CHEMBL1221944 | 17643111 |
Page: 1 |